OTCMKTS:SSYNF Arcturis Data (SSYNF) Stock Price, News & Analysis → New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad) Free SSYNF Stock Alerts $0.0002 0.00 (0.00%) (As of 04/18/2024 ET) Add Compare Share Share Today's Range$0.0002▼$0.000250-Day Range N/A52-Week Range$0.0002▼$0.0002VolumeN/AAverage Volume136,467 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartStock AnalysisChart Get Arcturis Data alerts: Email Address Ad InvestorPlaceNew crypto project uncovers 2,050% in 65 daysDuring the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.Just click here to sign up and be among the first to get it. About Arcturis Data Stock (OTCMKTS:SSYNF)Arcturis Data Limited, a healthcare technology company, develops software products that connects healthcare professionals with patients in the United Kingdom and the United States. Its products include CVm-Health, a web-based application for Covid-19 self-monitoring; DBm-Health, a patient to clinician system that allows health care professionals manage patients with diabetes; GDm-Health, a prescribed digital therapeutic for remote management of diabetes in pregnancy; and BPm-Health that allows pregnant women to self-monitor blood pressure during pregnancy. The company's products also include MagnifEye that allows reading and analysis of diagnostic tests; SEND, an evidence-based digital charting system for vital-signs observations; EDGE, a prescribed digital therapeutic for monitoring chronic obstructive pulmonary disease at home; CleanSpace, a system for monitoring personal exposure to air pollution; Support-HF, a prescribed digital therapeutic for monitoring heart failure at home; Sense, a clinical AI algorithm engine; SYNE-COV, a COVID-19 patient outcome algorithm; and SYNE-OPS, a real-time operational patient management algorithm. It has strategic research alliance with Bayer and Roche; collaboration agreement with Alexion to study the prevalence and outcomes of patients in certain disease areas; research collaboration agreement with Bristol Myers Squibb to apply machine learning for rare blood disease research; research agreement with University of Oxford to conduct a multi-omics drug discovery research project in asthma; strategic research agreement with Milton Keynes University Hospital, Somerset, Hampshire, Royal Wolverhampton, and Royal Devon and Exeter NHS Trusts. The company was formerly known as Sensyne Health Limited and changed its name to Arcturis Data Limited in October 2022. Arcturis Data Limited was incorporated in 2018 and is based in Oxford, the United Kingdom.Read More SSYNF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SSYNF Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com Receive SSYNF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcturis Data and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Health Information Services Sub-IndustryN/A Current SymbolOTCMKTS:SSYNF CUSIPN/A CIKN/A Webwww.sensynehealth.com Phone44-33-0058-1845FaxN/AEmployees158Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Richard Joseph Pye (Age 47)CFO & Executive Director Comp: $330.83kProf. Lionel Tarassenko CBEFREng, Director of R&D, Non-Executive Director and Member of Scientific Advisory BoardMr. Alexander Charles Wallace Snow (Age 55)CEO & Director Ms. Laura HillierCOO, General Counsel & Company SecretaryMs. Julia WilsonDirector of Investor RelationsDr. Nick Scott-Ram M.A.M.B.E., Ph.D., Chief of Analytics, Partnerships & DeliveryMore ExecutivesKey CompetitorsAclarionNASDAQ:ACONWAscomOTCMKTS:ACMLFBinovi TechnologiesOTCMKTS:BNVIFBrightSpring Health ServicesNASDAQ:BTSGUBullfrog AINASDAQ:BFRGWView All Competitors SSYNF Stock Analysis - Frequently Asked Questions How have SSYNF shares performed in 2024? Arcturis Data's stock was trading at $0.0002 at the beginning of 2024. Since then, SSYNF stock has increased by 0.0% and is now trading at $0.0002. View the best growth stocks for 2024 here. How do I buy shares of Arcturis Data? Shares of SSYNF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:SSYNF) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingBiden’s $374B Giveaway Into This SectorDTIThe “Perfect Storm” for GoldGold Safe ExchangeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHe Is Giving Away BitcoinCrypto Swap ProfitsThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcturis Data Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.